These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 17508005)
1. CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease. Fevery S; Billiau AD; Sprangers B; Rutgeerts O; Lenaerts C; Goebels J; Landuyt W; Kasran A; Boon L; Sagaert X; De Wolf-Peeters C; Waer M; Vandenberghe P Leukemia; 2007 Jul; 21(7):1451-9. PubMed ID: 17508005 [TBL] [Abstract][Full Text] [Related]
2. Murine bone marrow chimeras developing autoimmunity after CTLA-4-blockade show an expansion of T regulatory cells with an activated cytokine profile. De Somer L; Fevery S; Bullens DM; Rutgeerts O; Lenaerts C; Mathieu C; Boon L; Kasran A; Waer M; Billiau AD Immunol Lett; 2010 Sep; 133(1):49-53. PubMed ID: 20600326 [TBL] [Abstract][Full Text] [Related]
3. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. Xia G; Truitt RL; Johnson BD Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723 [TBL] [Abstract][Full Text] [Related]
4. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation. Li JM; Waller EK Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532 [TBL] [Abstract][Full Text] [Related]
5. Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10). Ildstad ST; Wren SM; Bluestone JA; Barbieri SA; Stephany D; Sachs DH J Immunol; 1986 Jan; 136(1):28-33. PubMed ID: 2933464 [TBL] [Abstract][Full Text] [Related]
6. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Truitt RL; Atasoylu AA Bone Marrow Transplant; 1991 Jul; 8(1):51-8. PubMed ID: 1833016 [TBL] [Abstract][Full Text] [Related]
7. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease. Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919 [TBL] [Abstract][Full Text] [Related]
8. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Wekerle T; Kurtz J; Ito H; Ronquillo JV; Dong V; Zhao G; Shaffer J; Sayegh MH; Sykes M Nat Med; 2000 Apr; 6(4):464-9. PubMed ID: 10742157 [TBL] [Abstract][Full Text] [Related]
10. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Johnson BD; Drobyski WR; Truitt RL Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480 [TBL] [Abstract][Full Text] [Related]
11. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model. Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433 [TBL] [Abstract][Full Text] [Related]
12. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation. Li JM; Gorechlad J; Larsen CP; Waller EK Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205 [TBL] [Abstract][Full Text] [Related]
13. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2. Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666 [TBL] [Abstract][Full Text] [Related]
14. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Jones SC; Murphy GF; Korngold R Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217 [TBL] [Abstract][Full Text] [Related]
15. Selective depletion of alloreactive T lymphocytes using patient-derived nonhematopoietic stimulator cells in allograft engineering. Nonn M; Herr W; Khan S; Todorova M; Link I; Thies J; Distler E; Kaltwasser M; Hoffmann J; Huber C; Hartwig UF Transplantation; 2008 Nov; 86(10):1427-35. PubMed ID: 19034014 [TBL] [Abstract][Full Text] [Related]
16. Induction of early post-transplant graft-versus-leukemia effects using intentionally mismatched donor lymphocytes and elimination of alloantigen-primed donor lymphocytes for prevention of graft-versus-host disease. Yang I; Weiss L; Abdul-Hai A; Kasir J; Reich S; Slavin S Cancer Res; 2005 Nov; 65(21):9735-40. PubMed ID: 16266994 [TBL] [Abstract][Full Text] [Related]
17. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution. Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113 [TBL] [Abstract][Full Text] [Related]
18. Effects of T cell depletion in radiation bone marrow chimeras. III. Characterization of allogeneic bone marrow cell populations that increase allogeneic chimerism independently of graft-vs-host disease in mixed marrow recipients. Sykes M; Chester CH; Sundt TM; Romick ML; Hoyles KA; Sachs DH J Immunol; 1989 Dec; 143(11):3503-11. PubMed ID: 2584703 [TBL] [Abstract][Full Text] [Related]
19. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen. Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959 [TBL] [Abstract][Full Text] [Related]
20. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways. Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]